ArticleThrombosis research2026
Blood product supplementation modulates clotting kinetics, mechanics, and fibrin architecture in an in vitro model of trauma-induced coagulopathy.
Article in Thrombosis research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTrauma-induced coagulopathy (TIC) worsens patient outcomes and increases transfusion requirements. Resuscitation strategies following injury have evolved to improve clinical outcomes. However, the mechanisms by which these strategies impact coagulation and whether they restore native coagulation in the presence of TIC are poorly understood.
methodsWe compared coagulation parameters and vital signs of patients who did (n = 26) and did not (n = 37) receive transfusion following injury. Transfusion products administered to patients were recreated in vitro, and their influence on a simulated model of TIC was measured. Optical turbidity, rheology, thromboelastography, and confocal microscopy were used to evaluate the clotting properties of platelet-poor plasma and whole blood models of hypocoagulable and hypercoagulable TIC. Transfusion models were supplemented with Saline, Plasma, Fibrinogen Concentrate, or Red Blood Cells (RBC).
resultsTransfused patients exhibited faster time to mortality, clot stiffness, and fibrinogen concentration compared to non-transfused patients. In the simulated transfusion model, saline reduced clot stiffness, increased fibrinolytic rate, and affected network structure. Plasma increased clot stiffness and density, and reduced fibrinolysis. Fibrinogen concentrate enhanced clot stiffness in plasma-based models but also increased fibrinolytic rate. RBC supplementation had variable impacts, causing weaker blood clots and accelerated fibrinolysis in hypocoagulable models, but delayed fibrinolysis in hypercoagulable models. DISCUSSION: Resuscitation products exert context-dependent effects on clot formation and breakdown that may not restore hemostasis during TIC. Saline induced dilutional hypocoagulability and increased clot failure risk, plasma enhanced clot stability, fibrinogen improved clot formation, and RBCs exerted endogenous coagulation-specific effects. These results support coagulation phenotyping to guide targeted transfusion strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.